Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________________________________

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 28, 2017
 
ABBVIE INC.
(Exact name of registrant as specified in its charter)
 
 _____________________________________________________

Delaware
 
001-35565
 
32-0375147
(State or other Jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
 
 
 
Identification No.)
 _____________________________________________________

1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (847) 932-7900
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 





Item 2.02.  Results of Operations and Financial Condition
 
On July 28, 2017, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2017.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits
Exhibit No.
 
Exhibit
99.1
 
Press Release dated July 28, 2017 (furnished pursuant to Item 2.02).





SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
ABBVIE INC.
 
 
 
 
Date:
July 28, 2017
By:
/s/ William J. Chase
 
 
 
William J. Chase
 
 
 
Executive Vice President,
 
 
 
Chief Financial Officer




EXHIBIT INDEX
 
Exhibit No.
 
Exhibit
99.1
 
Press Release dated July 28, 2017 (furnished pursuant to Item 2.02).